Volume Spike Investor

Myriad Genetics (NASDAQ: MYGN) is seeing strong selling pressure in the pre-market hours this Monday. The culprit is that plans to discontinue the development of Alzheimer treatment Flurizan after its late-stage trial failed to meet endpoints.
The stock has recovered off of its lows as shares had briefly been down more than 10%.  Shares are currently [...]